OTCMKTS:AKAOQ

Achaogen Competitors

$0.03

0.00 (-0.37 %)

(As of 04/14/2021 02:51 PM ET)

Add

Compare

Today's Range

$0.02

Now: $0.03▼

$0.03

50-Day Range

$0.02

MA: $0.03▼

$0.04

52-Week Range

$0.00

Now: $0.03▼

$0.05

Volume20,773 shs

Average Volume248,455 shs

Market Capitalization$1.30 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.84

Achaogen (OTCMKTS:AKAOQ) Vs. IPCIF, BCTXF, FWDG, ABMC, AMBS, and AKRXQ

Should you be buying AKAOQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Achaogen, including Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), FutureWorld (FWDG), American Bio Medica (ABMC), Amarantus BioScience (AMBS), and Akorn (AKRXQ).

Achaogen vs. Intellipharmaceutics International Stock

Achaogen (OTCMKTS:AKAOQ) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Achaogen has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Achaogen and Intellipharmaceutics International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achaogen	0	0	0	0	N/A
Intellipharmaceutics International	0	0	0	0	N/A

Valuation and Earnings

This table compares Achaogen and Intellipharmaceutics International's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achaogen	$8.73 million	0.15	$-186,510,000.00	N/A	N/A
Intellipharmaceutics International	$3.48 million	1.57	$-8,090,000.00	N/A	N/A

Intellipharmaceutics International has lower revenue, but higher earnings than Achaogen.

Insider and Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Achaogen and Intellipharmaceutics International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Achaogen	N/A	N/A	N/A
Intellipharmaceutics International	-232.11%	N/A	-81.71%

Summary

Achaogen beats Intellipharmaceutics International on 5 of the 8 factors compared between the two stocks.

Achaogen vs. BriaCell Therapeutics Stock

Achaogen (OTCMKTS:AKAOQ) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Achaogen and BriaCell Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Achaogen	N/A	N/A	N/A
BriaCell Therapeutics	N/A	N/A	-786.77%

Insider & Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are owned by institutional investors. 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Achaogen and BriaCell Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achaogen	0	0	0	0	N/A
BriaCell Therapeutics	0	0	0	0	N/A

Valuation & Earnings

This table compares Achaogen and BriaCell Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achaogen	$8.73 million	0.15	$-186,510,000.00	N/A	N/A
BriaCell Therapeutics	N/A	N/A	$-3,680,000.00	N/A	N/A

BriaCell Therapeutics has lower revenue, but higher earnings than Achaogen.

Volatility & Risk

Achaogen has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Achaogen vs. FutureWorld Stock

Achaogen (OTCMKTS:AKAOQ) and FutureWorld (OTCMKTS:FWDG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Achaogen and FutureWorld's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Achaogen	N/A	N/A	N/A
FutureWorld	N/A	N/A	N/A

Insider & Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Achaogen and FutureWorld, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achaogen	0	0	0	0	N/A
FutureWorld	0	0	0	0	N/A

Valuation & Earnings

This table compares Achaogen and FutureWorld's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achaogen	$8.73 million	0.15	$-186,510,000.00	N/A	N/A
FutureWorld	N/A	N/A	N/A	N/A	N/A

FutureWorld has lower revenue, but higher earnings than Achaogen.

Volatility & Risk

Achaogen has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500. Comparatively, FutureWorld has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Summary

Achaogen beats FutureWorld on 3 of the 4 factors compared between the two stocks.

Achaogen vs. American Bio Medica Stock

American Bio Medica (OTCMKTS:ABMC) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

American Bio Medica has a beta of -1.45, meaning that its stock price is 245% less volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for American Bio Medica and Achaogen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Bio Medica	0	0	0	0	N/A
Achaogen	0	0	0	0	N/A

Earnings & Valuation

This table compares American Bio Medica and Achaogen's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Bio Medica	$3.65 million	1.18	$-680,000.00	N/A	N/A
Achaogen	$8.73 million	0.15	$-186,510,000.00	N/A	N/A

American Bio Medica has higher earnings, but lower revenue than Achaogen.

Insider & Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 13.0% of American Bio Medica shares are owned by company insiders. Comparatively, 7.8% of Achaogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares American Bio Medica and Achaogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
American Bio Medica	-18.99%	N/A	-35.34%
Achaogen	N/A	N/A	N/A

Summary

Achaogen beats American Bio Medica on 5 of the 8 factors compared between the two stocks.

Achaogen vs. Amarantus BioScience Stock

Amarantus BioScience (OTCMKTS:AMBS) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

Amarantus BioScience has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Achaogen has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Profitability

This table compares Amarantus BioScience and Achaogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarantus BioScience	N/A	N/A	N/A
Achaogen	N/A	N/A	N/A

Earnings & Valuation

This table compares Amarantus BioScience and Achaogen's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarantus BioScience	N/A	N/A	N/A	N/A	N/A
Achaogen	$8.73 million	0.15	$-186,510,000.00	N/A	N/A

Amarantus BioScience has higher earnings, but lower revenue than Achaogen.

Analyst Recommendations

This is a summary of recent ratings for Amarantus BioScience and Achaogen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarantus BioScience	0	0	0	0	N/A
Achaogen	0	0	0	0	N/A

Insider & Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. Comparatively, 0.0% of Achaogen shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by company insiders. Comparatively, 7.8% of Achaogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Amarantus BioScience beats Achaogen on 2 of the 3 factors compared between the two stocks.

Achaogen vs. Akorn Stock

Akorn (OTCMKTS:AKRXQ) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Risk & Volatility

Akorn has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, meaning that its share price is 184% less volatile than the S&P 500.

Profitability

This table compares Akorn and Achaogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akorn	-54.01%	-5.13%	-0.49%
Achaogen	N/A	N/A	N/A

Valuation & Earnings

This table compares Akorn and Achaogen's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akorn	$682.43 million	0.01	$-226,770,000.00	N/A	N/A
Achaogen	$8.73 million	0.15	$-186,510,000.00	N/A	N/A

Achaogen has lower revenue, but higher earnings than Akorn.

Analyst Ratings

This is a summary of recent recommendations and price targets for Akorn and Achaogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akorn	0	0	0	0	N/A
Achaogen	0	0	0	0	N/A

Insider and Institutional Ownership

0.1% of Akorn shares are held by institutional investors. Comparatively, 0.0% of Achaogen shares are held by institutional investors. 3.9% of Akorn shares are held by company insiders. Comparatively, 7.8% of Achaogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Achaogen beats Akorn on 6 of the 9 factors compared between the two stocks.